MovDisordV3, PascalFrancis, Corpus, bibRecord, 001A59

Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression : Effect on quality of life

Identifieur interne : 001A59 ( PascalFrancis/Corpus ); précédent : 001A58; suivant : 001A60

Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression : Effect on quality of life

Auteurs : Angelo Antonini ; Silvana Tesei ; Anna Zecchinelli ; Paolo Barone ; Danilo De Gaspari ; Margherita Canesi ; Giorgio Sacilotto ; Nicoletta Meucci ; Claudio Mariani ; Gianni Pezzoli

Source :

Movement disorders [ 0885-3185 ] ; 2006.

RBID : Pascal:06-0435079

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Etat dépressif, Sertraline, Dose faible, Amitriptyline, Homme, Qualité vie.

English descriptors

KwdEn :
- Amitriptyline, Depression, Human, Low dose, Nervous system diseases, Parkinson disease, Quality of life, Sertraline.

Abstract

We assessed the effect of 3-month treatment of sertraline (50 mg) or low-dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single-blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS-17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS-17 score reduction > 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ-39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ-39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self-perception of motor function and further emphasizes the need for its treatment.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 21`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression : Effect on quality of life`
A11	`01`	`1`		`@1 ANTONINI (Angelo)`
A11	`02`	`1`		`@1 TESEI (Silvana)`
A11	`03`	`1`		`@1 ZECCHINELLI (Anna)`
A11	`04`	`1`		`@1 BARONE (Paolo)`
A11	`05`	`1`		`@1 DE GASPARI (Danilo)`
A11	`06`	`1`		`@1 CANESI (Margherita)`
A11	`07`	`1`		`@1 SACILOTTO (Giorgio)`
A11	`08`	`1`		`@1 MEUCCI (Nicoletta)`
A11	`09`	`1`		`@1 MARIANI (Claudio)`
A11	`10`	`1`		`@1 PEZZOLI (Gianni)`
A14	`01`			`@1 Parkinson Institute, Istituti Clinici di Perfezionamento @2 Milan @3 ITA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut. @Z 9 aut. @Z 10 aut.`
A14	`02`			`@1 Centro Parkinson, Dipartimento di Scienze Neurologiche, Università Federico II @2 Napoli @3 ITA @Z 4 aut.`
A20				`@1 1119-1122`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000142193570100`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 17 ref.`
A47	`01`	`1`		`@0 06-0435079`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 We assessed the effect of 3-month treatment of sertraline (50 mg) or low-dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single-blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS-17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS-17 score reduction > 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ-39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ-39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self-perception of motor function and further emphasizes the need for its treatment.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17F`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinson maladie @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @5 02`
C03	`03`	`X`	`FRE`	`@0 Etat dépressif @5 03`
C03	`03`	`X`	`ENG`	`@0 Depression @5 03`
C03	`03`	`X`	`SPA`	`@0 Estado depresivo @5 03`
C03	`04`	`X`	`FRE`	`@0 Sertraline @2 NK @2 FR @5 09`
C03	`04`	`X`	`ENG`	`@0 Sertraline @2 NK @2 FR @5 09`
C03	`04`	`X`	`SPA`	`@0 Sertralina @2 NK @2 FR @5 09`
C03	`05`	`X`	`FRE`	`@0 Dose faible @5 10`
C03	`05`	`X`	`ENG`	`@0 Low dose @5 10`
C03	`05`	`X`	`SPA`	`@0 Dosis débil @5 10`
C03	`06`	`X`	`FRE`	`@0 Amitriptyline @2 NK @2 FR @5 11`
C03	`06`	`X`	`ENG`	`@0 Amitriptyline @2 NK @2 FR @5 11`
C03	`06`	`X`	`SPA`	`@0 Amitriptilina @2 NK @2 FR @5 11`
C03	`07`	`X`	`FRE`	`@0 Homme @5 12`
C03	`07`	`X`	`ENG`	`@0 Human @5 12`
C03	`07`	`X`	`SPA`	`@0 Hombre @5 12`
C03	`08`	`X`	`FRE`	`@0 Qualité vie @5 13`
C03	`08`	`X`	`ENG`	`@0 Quality of life @5 13`
C03	`08`	`X`	`SPA`	`@0 Calidad vida @5 13`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Trouble humeur @5 41`
C07	`05`	`X`	`ENG`	`@0 Mood disorder @5 41`
C07	`05`	`X`	`SPA`	`@0 Trastorno humor @5 41`
N21				`@1 289`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0435079 INIST
ET :	Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression : Effect on quality of life
AU :	ANTONINI (Angelo); TESEI (Silvana); ZECCHINELLI (Anna); BARONE (Paolo); DE GASPARI (Danilo); CANESI (Margherita); SACILOTTO (Giorgio); MEUCCI (Nicoletta); MARIANI (Claudio); PEZZOLI (Gianni)
AF :	Parkinson Institute, Istituti Clinici di Perfezionamento/Milan/Italie (1 aut., 2 aut., 3 aut., 5 aut., 6 aut., 7 aut., 8 aut., 9 aut., 10 aut.); Centro Parkinson, Dipartimento di Scienze Neurologiche, Università Federico II/Napoli/Italie (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 8; Pp. 1119-1122; Bibl. 17 ref.
LA :	Anglais
EA :	We assessed the effect of 3-month treatment of sertraline (50 mg) or low-dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single-blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS-17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS-17 score reduction > 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ-39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ-39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self-perception of motor function and further emphasizes the need for its treatment.
CC :	002B17; 002B17G; 002B17F
FD :	Système nerveux pathologie; Parkinson maladie; Etat dépressif; Sertraline; Dose faible; Amitriptyline; Homme; Qualité vie
FG :	Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Trouble humeur
ED :	Nervous system diseases; Parkinson disease; Depression; Sertraline; Low dose; Amitriptyline; Human; Quality of life
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Mood disorder
SD :	Sistema nervioso patología; Parkinson enfermedad; Estado depresivo; Sertralina; Dosis débil; Amitriptilina; Hombre; Calidad vida
LO :	INIST-20953.354000142193570100
ID :	06-0435079

Links to Exploration step

Pascal:06-0435079

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression : Effect on quality of life</title>
<author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tesei, Silvana" sort="Tesei, Silvana" uniqKey="Tesei S" first="Silvana" last="Tesei">Silvana Tesei</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zecchinelli, Anna" sort="Zecchinelli, Anna" uniqKey="Zecchinelli A" first="Anna" last="Zecchinelli">Anna Zecchinelli</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name>
<affiliation><inist:fA14 i1="02"><s1>Centro Parkinson, Dipartimento di Scienze Neurologiche, Università Federico II</s1>
<s2>Napoli</s2>
<s3>ITA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Gaspari, Danilo" sort="De Gaspari, Danilo" uniqKey="De Gaspari D" first="Danilo" last="De Gaspari">Danilo De Gaspari</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sacilotto, Giorgio" sort="Sacilotto, Giorgio" uniqKey="Sacilotto G" first="Giorgio" last="Sacilotto">Giorgio Sacilotto</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Meucci, Nicoletta" sort="Meucci, Nicoletta" uniqKey="Meucci N" first="Nicoletta" last="Meucci">Nicoletta Meucci</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mariani, Claudio" sort="Mariani, Claudio" uniqKey="Mariani C" first="Claudio" last="Mariani">Claudio Mariani</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0435079</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0435079 INIST</idno>
<idno type="RBID">Pascal:06-0435079</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A59</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression : Effect on quality of life</title>
<author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tesei, Silvana" sort="Tesei, Silvana" uniqKey="Tesei S" first="Silvana" last="Tesei">Silvana Tesei</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zecchinelli, Anna" sort="Zecchinelli, Anna" uniqKey="Zecchinelli A" first="Anna" last="Zecchinelli">Anna Zecchinelli</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name>
<affiliation><inist:fA14 i1="02"><s1>Centro Parkinson, Dipartimento di Scienze Neurologiche, Università Federico II</s1>
<s2>Napoli</s2>
<s3>ITA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Gaspari, Danilo" sort="De Gaspari, Danilo" uniqKey="De Gaspari D" first="Danilo" last="De Gaspari">Danilo De Gaspari</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sacilotto, Giorgio" sort="Sacilotto, Giorgio" uniqKey="Sacilotto G" first="Giorgio" last="Sacilotto">Giorgio Sacilotto</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Meucci, Nicoletta" sort="Meucci, Nicoletta" uniqKey="Meucci N" first="Nicoletta" last="Meucci">Nicoletta Meucci</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mariani, Claudio" sort="Mariani, Claudio" uniqKey="Mariani C" first="Claudio" last="Mariani">Claudio Mariani</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name>
<affiliation><inist:fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amitriptyline</term>
<term>Depression</term>
<term>Human</term>
<term>Low dose</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Quality of life</term>
<term>Sertraline</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Etat dépressif</term>
<term>Sertraline</term>
<term>Dose faible</term>
<term>Amitriptyline</term>
<term>Homme</term>
<term>Qualité vie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We assessed the effect of 3-month treatment of sertraline (50 mg) or low-dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single-blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS-17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS-17 score reduction > 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ-39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ-39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self-perception of motor function and further emphasizes the need for its treatment.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression : Effect on quality of life</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ANTONINI (Angelo)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>TESEI (Silvana)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ZECCHINELLI (Anna)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BARONE (Paolo)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>DE GASPARI (Danilo)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CANESI (Margherita)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SACILOTTO (Giorgio)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MEUCCI (Nicoletta)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>MARIANI (Claudio)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>PEZZOLI (Gianni)</s1>
</fA11>
<fA14 i1="01"><s1>Parkinson Institute, Istituti Clinici di Perfezionamento</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Centro Parkinson, Dipartimento di Scienze Neurologiche, Università Federico II</s1>
<s2>Napoli</s2>
<s3>ITA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>1119-1122</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000142193570100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>17 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0435079</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We assessed the effect of 3-month treatment of sertraline (50 mg) or low-dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single-blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS-17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS-17 score reduction > 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ-39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ-39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self-perception of motor function and further emphasizes the need for its treatment.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Etat dépressif</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Depression</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Estado depresivo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Sertraline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Sertraline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Sertralina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Dose faible</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Low dose</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Dosis débil</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Amitriptyline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Amitriptyline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Amitriptilina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Qualité vie</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Quality of life</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Calidad vida</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Trouble humeur</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>41</s5>
</fC07>
<fN21><s1>289</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0435079 INIST</NO>
<ET>Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression : Effect on quality of life</ET>
<AU>ANTONINI (Angelo); TESEI (Silvana); ZECCHINELLI (Anna); BARONE (Paolo); DE GASPARI (Danilo); CANESI (Margherita); SACILOTTO (Giorgio); MEUCCI (Nicoletta); MARIANI (Claudio); PEZZOLI (Gianni)</AU>
<AF>Parkinson Institute, Istituti Clinici di Perfezionamento/Milan/Italie (1 aut., 2 aut., 3 aut., 5 aut., 6 aut., 7 aut., 8 aut., 9 aut., 10 aut.); Centro Parkinson, Dipartimento di Scienze Neurologiche, Università Federico II/Napoli/Italie (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 8; Pp. 1119-1122; Bibl. 17 ref.</SO>
<LA>Anglais</LA>
<EA>We assessed the effect of 3-month treatment of sertraline (50 mg) or low-dose amitriptyline (25 mg) on depression and quality of life in 31 patients with Parkinson's disease in a prospective single-blind randomized study. Both drugs significantly reduced the Hamilton Depression Rating Scale (HDRS-17) score. Completion rate was 75% for sertraline (12 of 16) and 73% for amitriptyline (11 of 15). Responder rate (HDRS-17 score reduction > 50%) was 83.3% for sertraline and 72.7% for amitriptyline. Sertraline but not amitriptyline treatment determined a significant benefit on quality of life (PDQ-39 scale). We found no change in Unified Parkinson's Disease Rating Scale scores. However, the improvement in specific PDQ-39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self-perception of motor function and further emphasizes the need for its treatment.</EA>
<CC>002B17; 002B17G; 002B17F</CC>
<FD>Système nerveux pathologie; Parkinson maladie; Etat dépressif; Sertraline; Dose faible; Amitriptyline; Homme; Qualité vie</FD>
<FG>Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Trouble humeur</FG>
<ED>Nervous system diseases; Parkinson disease; Depression; Sertraline; Low dose; Amitriptyline; Human; Quality of life</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Mood disorder</EG>
<SD>Sistema nervioso patología; Parkinson enfermedad; Estado depresivo; Sertralina; Dosis débil; Amitriptilina; Hombre; Calidad vida</SD>
<LO>INIST-20953.354000142193570100</LO>
<ID>06-0435079</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A59 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001A59 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0435079
   |texte=   Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression : Effect on quality of life
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression : Effect on quality of life

Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression : Effect on quality of life

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri